Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380304 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL11086636 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL29420836 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL376394 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL23942769 | 0.78 | ALDH1A1 (0.39) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL15257962 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL24068622 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL30605033 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL28477092 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL12466516 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115707689-A | Favipiravir impurity, preparation method and control method thereof | 浙江华海药业股份有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-115598242-A | HPLC (high performance liquid chromatography) detection method for contents of Favipiravir and key intermediates thereof | 合肥利夫生物科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| WO-2022009036-A1 | SYNTHESIS OF FAVIPIRAVIR | OPTIMUS DRUGS (P) LTD (IN) | 2022-01-13 | — | — | WO | claimed |
| WO-2021240295-A1 | PROCESS FOR PREPARATION OF FAVIPIRAVIR | GLENMARK LIFE SCIENCES LIMITED (IN) | 2021-12-02 | — | — | WO | claimed |
| CN-106866553-B | Synthesis method of Favipiravir | 中南大学 | 2020-02-04 | — | — | CN | claimed |
| CN-106866553-A | A kind of synthetic method of Favipiravir | 中南大学 | 2017-06-20 | — | — | CN | claimed |
| CN-106588786-A | Preparation method of high purity favipiravir impurity | 山东省药学科学院 | 2017-04-26 | — | — | CN | claimed |
| WO-2025039676-A1 | PAN-KRAS PROTEIN TARGETED DEGRADER COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-115636796-B | Preparation method of fampicin | 新发药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024084447-A2 | AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-2192117-A1 | ORGANIC AMINE SALT OF 6-FLUORO-3-HYDROXY-2-PYRAZINECARBONITRILE AND METHOD FOR PRODUCING THE SAME | Toyama Chemical Co., Ltd. (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-1295890-B1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1256588-B1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO LTD (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-6800629-B2 | VIRICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1295890-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1256588-A1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | ALDH1A1 348/4885KDM4E 1880/4885POLB 2889/4885 |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | GTF3C5, EIF2AK2, GTF3C2 | ALDH1A1 734/4885KDM4E 1860/4885POLB 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.